IN CASE YOU MISSED IT: The Washington Examiner published the below op-ed on Friday by Charles Duan, Director of Technology and Innovation Policy at the R Street Institute, examining many ways the STRONGER Patents Act would be disastrous for the patent system, enabling Big Pharma to expand their rampant patent abuse, and for American patients, who will […]

Continue Reading

IN CASE YOU MISSED IT: CNN published the op-ed below today by Lincoln Network co-founder, Garrett Johnson and Innovation Defense Foundation president, Wayne Brough highlighting the importance of inter partes review (IPR) for canceling invalid patents which are a significant cause of the drug pricing crisis facing American patients. This op-ed echoes what CAPA has told lawmakers, that IPR is essential […]

Continue Reading

by Matthew Lane, Coalition Against Patent Abuse American innovation and ingenuity are an essential driver of key medical advancements. They improve countless lives through a myriad of cures and treatments. But with increasingly expensive prescription drug prices and treatments, thanks in no small part to the exploitative behavior of groups like Big Pharma to extend […]

Continue Reading

CAPA applauds Sen. Cornyn for standing up to Big Pharma and putting patients first IN CASE YOU MISSED IT: Bloomberg Government published this article today highlighting comments by CAPA’s Executive Director Matthew Lane applauding U.S. Senator John Cornyn and his efforts through the bipartisan legislation, the Affordable Prescriptions for Patients Act, he co-sponsored with Sen. Richard […]

Continue Reading

Journal of Law and the Biosciences Robin Feldman Published: 07 December 2018 Abstract Presenting the first comprehensive study of evergreening, this article examines the extent to which evergreening behavior—which can be defined as artificially extending the protection cliff—may contribute to the problem. The author analyses all drugs on the market between 2005 and 2015, combing […]

Continue Reading

The most effective way to reduce drug prices is by spurring more competition. Sadly, big pharma invests heavily in blocking competition and abusing the patent system to continue charging any price they want. In fact, drug makers are ringing in 2019 by raising the price of hundreds of drugs already on the market. That’s not innovation. That’s price gouging.

Continue Reading